法瑟姆制药

最新新闻

• 评级变动
  Raymond James Initiates Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2025/12/12
• Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $0.00 per Share, Vs. FactSet Est of $-0.19
  MT Newswires · 2026/7/30
• 评级变动
  Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• 评级变动
  Barclays Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• Barclays Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Raymond James Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)
  TipRanks · 2026/9/22
• 评级变动
  A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28
  \u5e02\u573a\u8d44\u8baf · 2026/5/1
• 评级变动
  Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $13 to $28
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 评级变动
  Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Raises Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 评级变动
  Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Cantor Fitzgerald Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/1/14
• 评级变动
  Stifel Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/1/15
• 评级变动
  Barclays Upgrades Phathom Pharmaceuticals(PHAT.US) to Buy Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/3/27
• Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $22
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $22
  \u5e02\u573a\u8d44\u8baf · 2026/7/31

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。